{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:56:48Z","timestamp":1790791008897,"version":"4.1.0"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>SARS-CoV-2, the causative virus of the COVID-19 global pandemic, leads to a wide variety of responses among patients. Some of them present a very severe phenotype, while others only experience mild symptoms or are even asymptomatic. This differential prognosis is tightly related to the inflammatory status of the patient. Although WHO declared the end of the emergency, the pandemic caused a great socio-sanitary impact in all countries. Thus, the possible outbreak of new biological diseases in the future makes it necessary to deepen the knowledge of this uncontrolled immune response and look for reliable biomarkers to help us predict its potential health impact. Specialized pro-resolving lipid mediators (SPMs) as lipoxins are endogenous mediators synthesized from arachidonic acid in the resolution stage of any inflammatory process. These lipids have pro-resolving actions in several pathological models, including reducing NF-\u03baB-mediated inflammation, and inducing the antioxidant response through the Nrf-2 pathway. Thus, although a potential relationship has already been suggested between low levels of SPMs and COVID-19 severity, their true role as a predictive biomarker is still unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and results<\/jats:title><jats:p>In this study, we have analyzed by ELISA the serum levels of lipoxin A<jats:sub>4<\/jats:sub> (LXA<jats:sub>4<\/jats:sub>) in a representative Spanish cohort. We found reduced levels in deceased patients when compared to mild or severe patients, concomitant with a decrease in the LXA<jats:sub>4<\/jats:sub> biosynthetic pathway and an increase in its degradation pathway. Furthermore, we have studied the correlation between the levels of this SPM and several pathology indicators, finding a significant correlation between increased LXA<jats:sub>4<\/jats:sub> levels and a better prognosis of the patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We propose to measure systemic LXA<jats:sub>4<\/jats:sub> as a new promising biomarker to predict the survival in patients affected by SARS-CoV-2 and presumably to other viruses that can affect humanity in the future.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1509188","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T05:10:48Z","timestamp":1737609048000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Lipoxin A4 levels correlate with severity in a Spanish COVID-19 cohort: potential use of endogenous pro-resolving mediators as biomarkers"],"prefix":"10.3389","volume":"15","author":[{"given":"Sergio","family":"S\u00e1nchez-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael I.","family":"Ja\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Lozano-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Avenda\u00f1o-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Pascual\u2010Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hurtado-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"L\u00f3pez-Collazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisardo","family":"Bosc\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet (London England)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/POSTGRADMEDJ-2020-138577","article-title":"COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment","volume":"97","author":"Parasher","year":"2021","journal-title":"Postgrad Med J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/QMH.0000000000000398","article-title":"Guidelines for triage of COVID-19 patients presenting with multisystemic symptoms","volume":"32","author":"Alemi","year":"2023","journal-title":"Qual Manag Health Care"},{"key":"B5","article-title":"Features, Evaluation, and Treatment of Coronavirus (COVID-19)","author":"Cascella","year":"2023"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/S11684-020-0754-0","article-title":"Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection","volume":"14","author":"Zou","year":"2020","journal-title":"Front Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/S41586-020-2179-Y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2020.580987","article-title":"Heightened circulating interferon-inducible chemokines, and activated pro-cytolytic th1-cell phenotype features covid-19 aggravation in the second week of illness","volume":"11","author":"Tincati","year":"2020","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(20)30223-8","article-title":"COVID-19 cytokine storm syndrome: a threshold concept","volume":"2","author":"Chen","year":"2021","journal-title":"Lancet Microbe"},{"key":"B10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/JLB.3COVR0520-272R","article-title":"Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts","volume":"108","author":"Wang","year":"2020","journal-title":"J Leukoc Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/FCIMB.2022.922422","article-title":"Cytokine profiles associated with acute COVID-19 and long COVID-19 syndrome","volume":"12","author":"Queiroz","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2023.1170012","article-title":"Characterisation of the pro-inflammatory cytokine signature in severe COVID-19","volume":"14","author":"Hawerkamp","year":"2023","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/BMJEBM-2020-111536","article-title":"Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis","volume":"26","author":"Malik","year":"2021","journal-title":"BMJ Evidence-Based Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"8997709","DOI":"10.1155\/2022\/8997709","article-title":"D-dimer, CRP, PCT, and IL-6 levels at admission to ICU can predict in-hospital mortality in patients with COVID-19 pneumonia","volume":"2022","author":"Milenkovic","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1515\/JOM-2021-0103","article-title":"C-reactive protein levels associated with COVID-19 outcomes in the United States","volume":"121","author":"Lentner","year":"2021","journal-title":"J Osteopath Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-021-01519-7","article-title":"Severe acute respiratory syndrome coronavirus 2: the role of the main components of the innate immune system","volume":"44","author":"Anaeigoudari","year":"2021","journal-title":"Inflammation"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/S41590-021-01091-0","article-title":"Innate immunity: the first line of defense against SARS-CoV-2","volume":"23","author":"Diamond","year":"2022","journal-title":"Nat Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/J.IMMUNI.2014.02.009","article-title":"Proresolving lipid mediators and mechanisms in the resolution of acute inflammation","volume":"40","author":"Buckley","year":"2014","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4757-0937-7_1","article-title":"Lipoxins: a new series of eicosanoids (biosynthesis, stereochemistry, and biological activities)","volume":"229","author":"Serhan","year":"1988","journal-title":"Adv Exp Med Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900327","article-title":"12\/15-lipoxygenase counteracts inflammation and tissue damage in arthritis","volume":"183","author":"Kronke","year":"2009","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/PNAS.81.17.5335","article-title":"Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes","volume":"81","author":"Serhan","year":"1984","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B22","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/S41419-020-02846-7","article-title":"LXA4-FPR2 signaling regulates radiation-induced pulmonary fibrosis via crosstalk with TGF-\u03b2\/Smad signaling","volume":"11","author":"Kim","year":"2020","journal-title":"Cell Death Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"106982","DOI":"10.1016\/J.PHRS.2023.106982","article-title":"Lipoxin-mediated signaling: ALX\/FPR2 interaction and beyond","volume":"197","author":"S\u00e1nchez-Garc\u00eda","year":"2023","journal-title":"Pharmacol Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1042\/EBC20200018","article-title":"Specialized pro-resolving mediator network: an update on production and actions","volume":"64","author":"Chiang","year":"2020","journal-title":"Essays Biochem"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/prd.12034","article-title":"Natural resolution of inflammation","volume":"63","author":"Freire","year":"2013","journal-title":"Periodontol 2000"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/JIMMUNOL.0903526","article-title":"Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation","volume":"184","author":"Dufton","year":"2010","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M002863200","article-title":"Oxidoreductases in lipoxin A4 metabolic inactivation: A novel role for 15-oxoprostaglandin 13-reductase\/leukotriene B4 12-hydroxydehydrogenase in inflammation","volume":"275","author":"Clish","year":"2000","journal-title":"J Biol Chem"},{"key":"B28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5966\/SCTM.2015-0163","article-title":"Human periodontal stem cells release specialized proresolving mediators and carry immunomodulatory and prohealing properties regulated by lipoxins","volume":"5","author":"Cianci","year":"2016","journal-title":"Stem Cells Transl Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00777-10","article-title":"Lipoxin A4 inhibits porphyromonas gingivalis-induced aggregation and reactive oxygen species production by modulating neutrophil-platelet interaction and CD11b expression","volume":"79","author":"B\u00f6rgeson","year":"2011","journal-title":"Infect Immun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-007-7141-z","article-title":"BML-111, a lipoxin receptor agonist, modulates the immune response and reduces the severity of collagen-induced arthritis","volume":"57","author":"Zhang","year":"2008","journal-title":"Inflammation Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.plefa.2005.05.005","article-title":"Lipoxin A4 biology in the human synovium. Role of the ALX signaling pathways in modulation of inflammatory arthritis","volume":"73","author":"Fiore","year":"2005","journal-title":"Prostaglandins Leukot Essent Fat Acids"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043545","article-title":"Primary human airway epithelial cell-dependent inhibition of human lung mast cell degranulation","volume":"7","author":"Martin","year":"2012","journal-title":"PloS One"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1096\/fj.07-8653com","article-title":"Lipoxin A 4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism","volume":"21","author":"Levy","year":"2007","journal-title":"FASEB J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaci.2004.09.038","article-title":"Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound","volume":"115","author":"Vachier","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.abb.2018.04.016","article-title":"BML-111 alleviates acute lung injury through regulating the expression of lncRNA MALAT1","volume":"649","author":"Li","year":"2018","journal-title":"Arch Biochem Biophys"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1177\/1753425918785008","article-title":"Lipoxin A4 attenuates LPS-induced acute lung injury via activation of the ACE2-Ang-(1-7)-Mas axis","volume":"24","author":"Chen","year":"2018","journal-title":"Innate Immun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00079-2015","article-title":"Lipoxin A4 promotes lung epithelial repair whilst inhibiting fibroblast proliferation","volume":"2","author":"Zheng","year":"2016","journal-title":"ERJ Open Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/S12272-020-01299-Y","article-title":"Role of specialized pro-resolving lipid mediators and their receptors in virus infection: a promising therapeutic strategy for SARS-CoV-2 cytokine storm","volume":"44","author":"Lee","year":"2021","journal-title":"Arch Pharm Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2021.632238","article-title":"Specialized pro-resolving mediators as potential regulators of inflammatory macrophage responses in COVID-19","volume":"12","author":"Balta","year":"2021","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/BIOM14030296\/S1","article-title":"Association of altered plasma lipidome with disease severity in COVID-19 patients","volume":"14","author":"Zhang","year":"2024","journal-title":"Biomolecules"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.7150\/IJBS.75056","article-title":"Long COVID and its management","volume":"18","author":"Koc","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/SCIENCE.ADG7942","article-title":"Persistent complement dysregulation with signs of thromboinflammation in active Long Covid","volume":"383","author":"Cervia-Hasler","year":"2024","journal-title":"Science"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/CTM2.573","article-title":"The immune checkpoints storm in COVID-19: Role as severity markers at emergency department admission","volume":"11","author":"Avenda\u00f1o-Ortiz","year":"2021","journal-title":"Clin Transl Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/ALL.14657","article-title":"Risk factors for severe and critically ill COVID-19 patients: A review","volume":"76","author":"Gao","year":"2021","journal-title":"Allergy"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1159\/000358490","article-title":"Decreased levels of lipoxin A4 and annexin A1 in wheezy infants","volume":"163","author":"Eke Gungor","year":"2014","journal-title":"Int Arch Allergy Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/J.METABOL.2015.04.005","article-title":"Low blood and vitreal BDNF, LXA4 and altered Th1\/Th2 cytokine balance are potential risk factors for diabetic retinopathy","volume":"64","author":"Kaviarasan","year":"2015","journal-title":"Metabolism"},{"key":"B47","doi-asserted-by":"publisher","first-page":"102365","DOI":"10.1016\/J.PLEFA.2021.102365","article-title":"Low LXA4, RvD1 and RvE1 levels may be an indicator of the development of hypertension","volume":"174","author":"Y\u00fccel","year":"2021","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"B48","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1615\/CRITREVIMMUNOL.2020035652","article-title":"Immunological biomarkers of COVID-19","volume":"40","author":"Lei","year":"2020","journal-title":"Crit Rev Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3343\/ALM.2021.41.6.540","article-title":"Biomarkers for prognosis and treatment response in COVID-19 patients","volume":"41","author":"Bivona","year":"2021","journal-title":"Ann Lab Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"751","DOI":"10.5603\/CJ.A2022.0056","article-title":"Diagnostic value of lactate dehydrogenase in COVID-19: A systematic review and meta-analysis","volume":"29","author":"Fialek","year":"2022","journal-title":"Cardiol J"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/FCIMB.2023.1237277","article-title":"Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine","volume":"13","author":"Mao","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1177\/00031348221091940","article-title":"Correlation of D-dimer and outcomes in COVID-19 patients","volume":"88","author":"Nemec","year":"2022","journal-title":"Am Surg"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/IJCP.14970","article-title":"Effect of IL-6, IL-8\/CXCL8, IP-10\/CXCL 10 levels on the severity in COVID 19 infection","volume":"75","author":"Kesmez Can","year":"2021","journal-title":"Int J Clin Pract"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S357097","article-title":"Admission levels of serum P-selectin and IL-6 can predict development of deep venous thrombosis in hospitalized covid-19 patients","volume":"15","author":"Farouk","year":"2022","journal-title":"Int J Gen Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S10020-020-00230-X\/FIGURES\/5","article-title":"IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19","volume":"26","author":"Chen","year":"2020","journal-title":"Mol Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1096\/FJ.202100540R","article-title":"High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients","volume":"35","author":"Archambault","year":"2021","journal-title":"FASEB J"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/S10787-022-01070-3","article-title":"Potential role of lipoxin in the management of COVID-19: a narrative review","volume":"30","author":"Batiha","year":"2022","journal-title":"Inflammopharmacology"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/J.ARCMED.2020.09.006","article-title":"Bioactive lipids in COVID-19-further evidence","volume":"52","author":"Das","year":"2021","journal-title":"Arch Med Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHRS.2022.106618","article-title":"Prognostic impacts of Lipoxin A4 in patients with acute myocardial infarction: A prospective cohort study","volume":"187","author":"Chen","year":"2023","journal-title":"Pharmacol Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"12849","DOI":"10.1038\/S41598-020-69831-0","article-title":"Lipoxins, RevD1 and 9, 13 HODE as the most important derivatives after an early incident of ischemic stroke","volume":"10","author":"Szczuko","year":"2020","journal-title":"Sci Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12265","article-title":"Impaired resolution of inflammation in human chronic heart failure","volume":"44","author":"Reina-Couto","year":"2014","journal-title":"Eur J Clin Invest"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0142848","article-title":"Inverse relationship between serum lipoxin A4 level and the risk of metabolic syndrome in a middle-aged chinese population","volume":"10","author":"Yu","year":"2015","journal-title":"PloS One"},{"key":"B63","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/S41398-022-02208-1","article-title":"Age-linked suppression of lipoxin A4 associates with cognitive deficits in mice and humans","volume":"12","author":"Pamplona","year":"2022","journal-title":"Transl Psychiatry"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/8527305","article-title":"LipoxinA4 as a potential prognostic marker of COVID-19","volume":"2022","author":"Jamali","year":"2022","journal-title":"J Lipids"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2019.00719","article-title":"Regulation and functions of 15-lipoxygenases in human macrophages","volume":"10","author":"Snodgrass","year":"2019","journal-title":"Front Pharmacol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.838782","article-title":"Formation, Signaling and Occurrence of Specialized Pro-Resolving Lipid Mediators-What is the Evidence so far","volume":"2","author":"Scheb","year":"2022","journal-title":"Front Pharmacol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12903-024-03948-w","article-title":"Lipoxin A4 levels predict site-specific clinical improvements post scaling and root planing and correlate negatively with periodontal pathogens in severe periodontitis","volume":"24","author":"Ma","year":"2024","journal-title":"BMC Oral Health"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1109747","article-title":"The protective effects of lipoxin A4 on type 2 diabetes mellitus: A Chinese prospective cohort study","volume":"14","author":"Wang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-216475","article-title":"Dysregulation of prostaglandins, leukotrienes and lipoxin A4 in bronchiectasis","volume":"77","author":"Bedi","year":"2022","journal-title":"Thorax"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1509188\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T05:10:52Z","timestamp":1737609052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1509188\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":69,"alternative-id":["10.3389\/fimmu.2024.1509188"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1509188","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"article-number":"1509188"}}